Lixisenatide as add-on to oral anti-diabetic therapy: An effective treatment for glycaemic control with body weight benefits in type 2 diabetes

Denis Raccah, Pierre Gourdy, Luc Sagnard, Antonio Ceriello

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Achieving recommended glycated haemoglobin (HbA1c) targets in patients with type 2 diabetes mellitus (T2DM) requires effective control of fasting and post-prandial plasma glucose. As T2DM progresses, oral anti-diabetics are no longer sufficient to maintain glycaemic control. Five phase III studies in the GetGoal clinical trial programme assessed the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in combination with oral anti-diabetics in patients with T2DM insufficiently controlled using oral anti-diabetics. Methods: A meta-analysis was performed of the results of five 24-week clinical trials (comprising 2760 patients) concerning lixisenatide or placebo plus oral anti-diabetic therapy. The primary endpoint of these studies was change in HbA1c at week 24. Changes in fasting and post-prandial plasma glucose, and weight were also established as were the odds ratios for hypoglycaemia and composite safety and efficacy endpoints. Meta-analysis outcomes were assessed using a random effects model. All meta-analyses were performed using RevMan, version 5.1. Results: Lixisenatide was significantly better than placebo in terms of achieving all endpoints in this meta-analysis, including the primary endpoint change in HbA1c at week 24, with p

Original languageEnglish
Pages (from-to)742-748
Number of pages7
JournalDiabetes/Metabolism Research and Reviews
Volume30
Issue number8
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • Glycaemic control
  • Lixisenatide
  • Oral anti-diabetics
  • Prandial
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Lixisenatide as add-on to oral anti-diabetic therapy: An effective treatment for glycaemic control with body weight benefits in type 2 diabetes'. Together they form a unique fingerprint.

Cite this